FI3894012T3 - Kinaasin estäjän kidemuotoja ja suolamuotoja - Google Patents

Kinaasin estäjän kidemuotoja ja suolamuotoja

Info

Publication number
FI3894012T3
FI3894012T3 FIEP19836338.4T FI19836338T FI3894012T3 FI 3894012 T3 FI3894012 T3 FI 3894012T3 FI 19836338 T FI19836338 T FI 19836338T FI 3894012 T3 FI3894012 T3 FI 3894012T3
Authority
FI
Finland
Prior art keywords
degrees
compound
hemifumarate
xrpd pattern
following
Prior art date
Application number
FIEP19836338.4T
Other languages
English (en)
Finnish (fi)
Inventor
Frenel Demorin
Khalid Shah
Sagar Shakya
Peter Wong
Courtney Johnson
Melanie Bevill
Stephan Parent
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Application granted granted Critical
Publication of FI3894012T3 publication Critical patent/FI3894012T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP19836338.4T 2018-12-13 2019-12-12 Kinaasin estäjän kidemuotoja ja suolamuotoja FI3894012T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779430P 2018-12-13 2018-12-13
US201962856469P 2019-06-03 2019-06-03
PCT/US2019/065972 WO2020123800A1 (en) 2018-12-13 2019-12-12 Crystalline forms and salt forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
FI3894012T3 true FI3894012T3 (fi) 2025-09-18

Family

ID=69160358

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19836338.4T FI3894012T3 (fi) 2018-12-13 2019-12-12 Kinaasin estäjän kidemuotoja ja suolamuotoja

Country Status (33)

Country Link
US (2) US12017995B2 (cg-RX-API-DMAC7.html)
EP (2) EP4631505A3 (cg-RX-API-DMAC7.html)
JP (3) JP7509779B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250103803A (cg-RX-API-DMAC7.html)
CN (1) CN113329790A (cg-RX-API-DMAC7.html)
AU (2) AU2019395419B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011333A2 (cg-RX-API-DMAC7.html)
CA (1) CA3122840A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001537A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007613A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210375A (cg-RX-API-DMAC7.html)
DK (1) DK3894012T3 (cg-RX-API-DMAC7.html)
ES (1) ES3052838T3 (cg-RX-API-DMAC7.html)
FI (1) FI3894012T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20247596B (cg-RX-API-DMAC7.html)
HR (1) HRP20251122T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072868T2 (cg-RX-API-DMAC7.html)
IL (2) IL283860B2 (cg-RX-API-DMAC7.html)
LT (1) LT3894012T (cg-RX-API-DMAC7.html)
MA (1) MA54458B1 (cg-RX-API-DMAC7.html)
MD (1) MD3894012T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006951A (cg-RX-API-DMAC7.html)
PE (1) PE20211757A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551356A1 (cg-RX-API-DMAC7.html)
PL (1) PL3894012T4 (cg-RX-API-DMAC7.html)
PT (1) PT3894012T (cg-RX-API-DMAC7.html)
RS (1) RS67216B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105949RA (cg-RX-API-DMAC7.html)
SI (1) SI3894012T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500346T1 (cg-RX-API-DMAC7.html)
TW (2) TWI913821B (cg-RX-API-DMAC7.html)
WO (1) WO2020123800A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103844B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
KR102826380B1 (ko) * 2019-06-03 2025-06-26 엑셀리시스, 인코포레이티드 카이네이스 저해제의 결정질 염 형태
FI4143169T3 (fi) * 2020-04-30 2026-06-08 Exelixis Inc Kinaasi-inhibiittorin valmistusmenetelmät
PH12023550160A1 (en) 2020-07-31 2023-09-18 Exelixis Inc Combinations for the Treatment of Cancer
IL302485A (en) * 2020-11-05 2023-06-01 Exelixis Inc Kinase inhibitor pharmaceutical preparations
CN112650176B (zh) * 2020-12-22 2022-08-30 天能化工有限公司 一种盐酸解析开停车工序的dcs控制方法
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
AU2022420610A1 (en) 2021-12-22 2024-06-27 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
JP4667537B2 (ja) 2008-04-10 2011-04-13 大鵬薬品工業株式会社 アシルチオウレア化合物又はその塩、及びその用途
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
MX2019012505A (es) 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
HRP20251184T1 (hr) 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
KR102826380B1 (ko) * 2019-06-03 2025-06-26 엑셀리시스, 인코포레이티드 카이네이스 저해제의 결정질 염 형태

Also Published As

Publication number Publication date
JP2024038167A (ja) 2024-03-19
IL283860B2 (en) 2025-10-01
IL320433A (en) 2025-06-01
US20230029213A1 (en) 2023-01-26
HRP20251122T1 (hr) 2025-11-21
LT3894012T (lt) 2025-10-10
MX2021006951A (es) 2021-07-15
IL283860A (en) 2021-07-29
EP4631505A2 (en) 2025-10-15
AU2019395419A1 (en) 2021-07-01
CN113329790A (zh) 2021-08-31
JP7509779B2 (ja) 2024-07-02
GEP20247596B (en) 2024-02-26
PL3894012T3 (pl) 2026-01-05
KR20250103803A (ko) 2025-07-07
JP2026031599A (ja) 2026-02-24
EP4631505A3 (en) 2025-12-10
ZA202103844B (en) 2024-11-27
JP7783870B2 (ja) 2025-12-10
TW202039440A (zh) 2020-11-01
WO2020123800A1 (en) 2020-06-18
JP2022512399A (ja) 2022-02-03
KR20210102381A (ko) 2021-08-19
PL3894012T4 (pl) 2026-01-05
HUE072868T2 (hu) 2025-12-28
PH12021551356A1 (en) 2021-12-06
CO2021007613A2 (es) 2021-06-21
MA54458B1 (fr) 2025-09-30
RS67216B1 (sr) 2025-10-31
CL2021001537A1 (es) 2022-02-04
ES3052838T3 (en) 2026-01-15
CA3122840A1 (en) 2020-06-18
SI3894012T1 (sl) 2025-10-30
AU2025234277A1 (en) 2025-10-16
MA54458A (fr) 2021-10-20
SG11202105949RA (en) 2021-07-29
TWI913821B (zh) 2026-02-01
KR102828472B1 (ko) 2025-07-03
DK3894012T3 (da) 2025-09-15
PE20211757A1 (es) 2021-09-07
TWI852963B (zh) 2024-08-21
AU2019395419B2 (en) 2025-06-26
BR112021011333A2 (pt) 2021-08-31
MD3894012T2 (ro) 2025-11-30
US12679809B2 (en) 2026-07-14
EP3894012B1 (en) 2025-06-18
EP3894012A1 (en) 2021-10-20
TW202519513A (zh) 2025-05-16
SMT202500346T1 (it) 2025-11-10
CR20210375A (es) 2021-08-18
PT3894012T (pt) 2025-09-25
US12017995B2 (en) 2024-06-25
US20240300897A1 (en) 2024-09-12
IL283860B1 (en) 2025-06-01

Similar Documents

Publication Publication Date Title
ES2674174T3 (es) Antagonista de LPA1 policíclico y usos del mismo
IL258052A (en) Solid configurations of isoquinolinone derivatives, process for their preparation, compositions containing them and methods of use
Göker et al. Synthesis of some new 2-substituted-phenyl-1H-benzimidazole-5-carbonitriles and their potent activity against Candida species
HRP20251122T1 (hr) Kristalni oblici i oblici soli inhibitora kinaze
ZA202305593B (en) Crystalline form iii of melanocortin receptor agonist compound and method for preparing same
WO2008055013A3 (en) 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
MX2023004655A (es) Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma.
JOP20230084A1 (ar) الشكل البلوري iv لمركب ناهض مستقبلات الميلانوكورتين وطريقة تحضيره
HRP20140666T1 (hr) Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora
PE20110100A1 (es) Procedimiento de preparacion de n-[trans-4-[4-(ciclopropilmetil)-1-piperazinil]ciclohexil]-4-[[(7r)-7-etil-5,6,7,8-tetrahidro-5-metil-8-(1-metiletil)-6-oxo-2-pteridinil]amino]-3-metoxi-benzamida
MX2009001067A (es) Formas cristalinas de analogos de rapamicina.
IL214086A (en) Malt salt of n- {4 - {[7,6- bis (methyllaxy) quinoline-4-yl] oxy} phenyl) - n- (4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms for cancer treatment
MX2020009612A (es) Polimorfos de sal de calcio novedosos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
WO2020141419A3 (en) Novel salts and polymorphic form of bempedoic acid
JP2022512399A5 (cg-RX-API-DMAC7.html)
HRP20230813T1 (hr) Upadacitinib solni spoj i postupak njegove pripreme
CN103910663B (zh) 一种具有抗菌活性的截短侧耳素衍生物及其制备和应用
JP6713472B2 (ja) クロメノンモノカルボン酸トランスポータ阻害薬
AU2019334693B2 (en) Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor
NZ606042A (en) Process for the preparation of erlotinib and salts thereof
WO2020016302A8 (en) A xinafoate salt of a jak inhibiting compound
HRP20180865T1 (hr) Kristalni oblik abakavira koji uglavnom ne sadrži otapalo
MX2023013044A (es) Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma.
US3288792A (en) Method of preparing 2, 4-diamino-6-alkylpyrido (2, 3-d) pyrimidines
KR20090061972A (ko) 베포타스틴 p-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물